U.S., Aug. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07770828) titled 'Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD' on Aug. 13.
Brief Summary: This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
Study Start Date: Aug. 11
Study Type: INTERVENTIONAL
Condition:
Dry Age-related Macular Degeneration
Intervention:
BIOLOGICAL: OCU410
Subretinal Injection
Recruitment Status: RECRUITING
Sponsor: Ocugen
Disclaimer: Curated by HT Syndication....